All In Biotech

NDA 006488 · Fresenius Kabi USA

Xylocaine W/ Epinephrine

Epinephrine, Lidocaine Hydrochloride · Injection

Last checked: Nov 20, 2026Latest source record: Oct 30, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1948

Nov 19, 1948

Approved uses

1

Original approval plus efficacy supplements

Registered trials

2,347

454 Phase 3, 232 recruiting

FAERS reports

11,516

8,835 serious, 1,101 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 13, 2026.

INDICATIONS & USAGE Xylocaine (lidocaine HCl) Injections are indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed.

Therapeutic areas: Kidney and urology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 19, 1948 Original approval
11 products under this application
  • XYLOCAINE W/ EPINEPHRINE · EPINEPHRINE 0.005MG/ML; LIDOCAINE HYDROCHLORIDE 1% · INJECTABLE, INJECTION · Prescription
  • XYLOCAINE · LIDOCAINE HYDROCHLORIDE 0.5% · INJECTABLE, INJECTION · Prescription · TE AP
  • XYLOCAINE W/ EPINEPHRINE · EPINEPHRINE 0.005MG/ML; LIDOCAINE HYDROCHLORIDE 0.5% · INJECTABLE, INJECTION · Prescription · TE AP
  • XYLOCAINE W/ EPINEPHRINE · EPINEPHRINE 0.01MG/ML; LIDOCAINE HYDROCHLORIDE 1% · INJECTABLE, INJECTION · Prescription · TE AP
  • XYLOCAINE · LIDOCAINE HYDROCHLORIDE 1.5% · INJECTABLE, INJECTION · Prescription · TE AP
  • XYLOCAINE · LIDOCAINE HYDROCHLORIDE 2% · INJECTABLE, INJECTION · Prescription · TE AP
  • XYLOCAINE W/ EPINEPHRINE · EPINEPHRINE 0.005MG/ML; LIDOCAINE HYDROCHLORIDE 2% · INJECTABLE, INJECTION · Prescription · TE AP
  • XYLOCAINE W/ EPINEPHRINE · EPINEPHRINE 0.005MG/ML; LIDOCAINE HYDROCHLORIDE 1.5% · INJECTABLE, INJECTION · Prescription · TE AP
  • XYLOCAINE · LIDOCAINE HYDROCHLORIDE 1% · INJECTABLE, INJECTION · Prescription · TE AP
  • XYLOCAINE W/ EPINEPHRINE · EPINEPHRINE 0.02MG/ML; LIDOCAINE HYDROCHLORIDE 2% · INJECTABLE, INJECTION · Prescription · TE AP
  • XYLOCAINE W/ EPINEPHRINE · EPINEPHRINE 0.01MG/ML; LIDOCAINE HYDROCHLORIDE 2% · INJECTABLE, INJECTION · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Epinephrine" as an intervention, any sponsor and status, largest first.

All 2,347 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • infusion site pain793
  • nausea741
  • drug ineffective718
  • dyspnoea650
  • off label use630
  • diarrhoea584
  • headache579
  • pain562
  • fatigue530
  • infusion site erythema494
  • dizziness474
  • vomiting454

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004204
2005155
2006129
2007136
2008171
2009224
2010207
2011270
2012306
2013267
2014246
2015361
2016314
2017325
2018457
2019457
2020445
2021488
2022812
20231,193
20241,728
20251,615
20261,006

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • Current · updated Nov 18, 2026

    Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-37). Check wholesalers for inventory

  • Current · updated Nov 3, 2026

    Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-57). Check wholesalers for inventory

  • Current · updated Nov 18, 2026

    Xylocaine, Injection, 20 mg/1 mL (NDC 63323-496-97). Demand increase for the drug

  • Current · updated Nov 18, 2026

    Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-17). Check wholesalers for inventory

  • Current · updated Nov 18, 2026

    Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-31). Demand increase for the drug

  • Current · updated Nov 18, 2026

    Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-91). Demand increase for the drug

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Xylocaine (Lidocaine HCl)

2024 spending

$3K

Beneficiaries

281

306 claims

Per beneficiary

$11

$0.23 per unit

View as table
YearSpending
2020$6,191
2021$13,486
2022$16,868
2023$5,044
2024$3,109

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4,529 on PubMed

Sponsor: Fresenius Kabi USA · Also marketed as Xylocaine

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.